Michael Sabranski

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

Christian Hoffmann, Tanya Welz, Michael Sabranski et al. · HIV Medicine · 2016 · 281 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease

Christian Hoffmann, Holger Schmid, Markus Müller et al. · Blood · 2011 · 90 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +8

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

José M. Gatell, Lambert Assoumou, Graeme Moyle et al. · Clinical Infectious Diseases · 2018 · 48 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Treatment of AIDS-related lymphomas

Christoph Wyen, Björn‐Erik Ole Jensen, Marcus Hentrich et al. · AIDS · 2011 · 33 citations

Medicine, Infectious Diseases, Oncology +16

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

Ana Gonzalez‐Cordón, Lambert Assoumou, Graeme Moyle et al. · Journal of Antimicrobial Chemotherapy · 2021 · 27 citations · Full text

Veterinary Medicine, Pharmacology, Pharmacotherapy +17